LSTM Home > LSTM Research > LSTM Online Archive

Albendazole for the control and elimination of lymphatic filariasis: systematic review

Critchley, J., Addiss, D., Ejere, H., Gamble, C., Garner, Paul ORCID: https://orcid.org/0000-0002-0607-6941 and Gelband, H. (2005) 'Albendazole for the control and elimination of lymphatic filariasis: systematic review'. Tropical Medicine & International Health, Vol 10, Issue 9, pp. 818-825.

Full text not available from this repository.

Abstract

OBJECTIVES The Global Programme to Eliminate Lymphatic Filariasis recommends albendazole in combination with other antifilarial drugs. This systematic review examines albendazole in treatment and control of lymphatic filariasis.
DATA SOURCES The Cochrane Controlled Trials Register, MEDLINE and EMBASE to April 2005; contacting experts, international organisations and drug manufacturers.
METHODS Randomised or quasi-randomised controlled trials included; two reviewers independently assessed eligibility, quality, and extracted data. We calculated the relative risk of microfilaraemia (mf) prevalence using fixed effect, or random effects model in case of heterogeneity.
RESULTS Six trials met inclusion criteria. Three trials compared albendazole with placebo: no effect was demonstrated on mf prevalence, but density was lower in one of the three studies at 6 months. Three trials added albendazole to ivermectin, with no demonstrable effect; prevalence tended to be lower at 4-6 months but not at 12 months (4-6 months; RR 0.49, 95% CI 0.18 to 1.39, n = 255, 2 trials; 12 months: RR 1.00, 95% CI 0.88 to 1.13, n = 348, 2 trials). Mf density was significantly lower in two of the three trials; one of two trials measuring density at 12 months showed a difference. Three trials added albendazole to diethylcarbamazine; two were small trials with no difference demonstrated; the third study tended to favour combination at 6 months (RR = 0.62, 95% CI 0.32 to 1.21, n = 491), with a significant difference for density.
CONCLUSIONS The effect of albendazole against adult and larval filarial parasites, alone and in combination with other antifilarial drugs, deserves further rigorous research.

Item Type: Article
Uncontrolled Keywords: lymphatic filariasis albendazole systematic review mass drug administration wuchereria-bancrofti intestinal helminth haitian children ivermectin diethylcarbamazine combination efficacy infections
Subjects: QV Pharmacology > Anti-Inflammatory Agents. Anti-Infective Agents. Antineoplastic Agents > QV 250 Anti-infective agents (General)
QV Pharmacology > QV 38 Drug action.
QX Parasitology > Helminths. Annelida > QX 301 Filarioidea
WC Communicable Diseases > Tropical and Parasitic Diseases > WC 765 Prevention and control
WC Communicable Diseases > Tropical and Parasitic Diseases > WC 880 Filariasis and related conditions (General)
Faculty: Department: Groups (2002 - 2012) > International Health Group
Digital Object Identifer (DOI): https://doi.org/10.1111/j.1365-3156.2005.01458.x
Depositing User: Martin Chapman
Date Deposited: 13 Sep 2011 14:09
Last Modified: 06 Feb 2018 13:03
URI: https://archive.lstmed.ac.uk/id/eprint/1982

Statistics

View details

Actions (login required)

Edit Item Edit Item